Targeted intracellular degradation of SARS-CoV-2 via computationally optimized peptide fusions
Author(s)Chatterjee, Pranam; Ponnapati, Manvitha; Kramme, Christian; Plesa, Alexandru M.; Church, George M.; Jacobson, Joseph; ... Show more Show less
MetadataShow full item record
The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has elicited a global health crisis of catastrophic proportions. With only a few vaccines approved for early or limited use, there is a critical need for effective antiviral strategies. In this study, we report a unique antiviral platform, through computational design of ACE2-derived peptides which both target the viral spike protein receptor binding domain (RBD) and recruit E3 ubiquitin ligases for subsequent intracellular degradation of SARS-CoV-2 in the proteasome. Our engineered peptide fusions demonstrate robust RBD degradation capabilities in human cells and are capable of inhibiting infection-competent viral production, thus prompting their further experimental characterization and therapeutic development.
DepartmentMassachusetts Institute of Technology. Center for Bits and Atoms; Massachusetts Institute of Technology. Media Laboratory
Springer Science and Business Media LLC
Chattergee, Pranam et al. "Targeted intracellular degradation of SARS-CoV-2 via computationally optimized peptide fusions." Communications Biology 3, 1 (November 2020): 715 © 2020 The Author(s)
Final published version